EMA Updates Activities
The EMA has appointed Grzegorz Cessak as its vice-chair of management for the next three years.
The European Medicines Agency (EMA) has appointed Grzegorz Cessak as vice-chair of its management for the next three years. Cessak has been president of Poland’s Office for registration of Medicinal Products, Medical Devices and Biocidal Products since July 2009, and a member of EMA’s Management Board since January 2010. He steps into the role that was vacated by Christa Wirthumer-Hoche following her election as chair in March 2016. In other news, the agency provided an update on its program to support the development of promising medicines addressing unmet medical needs (PRIME). A total of 48 applications were received between its launch on March 7, 2016 and the end of June, and about another 70 applications have been submitted since mid-2016. Overall, the number of new applications for marketing authorization received in the first half of 2016 was comparable to that received during the same period in 2015 (42 in the first half 2016 vs. 45 in the first half 2015). EMA also said it is developing a multilingual European medicines web portal that will aim to provide access to free, reliable, and unbiased information for patients, consumers, caregivers, healthcare professionals, and academics on all medicines authorized in the European Union (EU). The site will provide details about a medicine across its lifecycle, from clinical trials to adverse drug reaction reports. Read the full release here
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
